Navigation Links
Belinostat in Medical News

CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA

- Conference call to be hosted on Tuesday, December 11th at 9:00 a.m. Eastern time - - Encouraging clinical results presented at ASH from the ongoing Phase II trial in T-cell lymphomas - - Positive End-of-Phase II meeting held with the FDA for b...

CuraGen Corporation Regains NASDAQ Listing Compliance

...in late January, we have successfully advanced our lead clinical program CR011-vcMMAE into Phase II development, completed the sale of our interest in belinostat for approximately $38 million in cash thus far, removed $50.9 million in debt from our balance sheet, and announced a reduction in our burn rate guida...

CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million

...of CuraGen Corporation. "We also retain further potential upside related to belinostat consisting of up to $6 million in potential milestone payments on future ne...raGen's potential economic benefits from future net sales and sublicense of belinostat may constitute forward-looking statements within the meaning of the Private...

CuraGen Reports Third Quarter 2007 Financial Results

...CR-NCI-EORTC International Conference. These results, along with additional belinostat data being reported in December at the 2007 ASH Annual Meeting, will allow ...company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over ...

CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference

...or the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promis...
Belinostat in Medical Technology

CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting

BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated preliminary clinical trial results from the Phase II study ...

CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference

- Significant anti-tumor activity of combination IV belinostat in ovarian cancer reported - - Oral belinostat demonstrated to be safe and well-tolerated in Phase I - - Presentation of results from two NCI-sponsored clinical trials - - CuraGen to provide a clinical up...

CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia

BRANFORD, Conn., Aug. 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, i...

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs

- Enrollment completed in Phase II trial evaluating a single dose of velafermin for the prevention of severe oral mucositis - - Continued focus to define registrational path for belinostat in the treatment of cancer - - Conference call and webcast to be held ...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of ...

CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

...0.67 per share, during the same period in 2007. Significant one time transactions during the second quarter of 2008 included the sale of the rights to belinostat to TopoTarget A/S for approximately $38 million in cash and the repurchase of $50.9 million of debt for $43.2 million in privately negotiated transact...

CuraGen Advances CR011-vcMMAE into Phase II

...rporation (Nasdaq: CRGN ) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising ...

CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma

...he four posters discussing Phase I and Phase II clinical trial results with belinostat being presented at the AACR-NCI-EORTC International Conference. Conference...company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over ...

CuraGen Announces Top-Line Phase II Results on Velafermin

...tics, October 22-26, 2007, in San Francisco, CA: belinostat Title: Phase II Multicenter Trial of belinostat (PXD101) in Combination with Carb...c Agents Title: A Phase I Study of Oral belinostat (PXD101) in Patients with Advance...

CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

...sentation discussing interim clinical results with belinostat will be made at the 2007 American Society of Clini...nd anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxe...mailto:info@curagen.com">info@curagen.com About belinostat ...
Belinostat in Biological News

Massey researchers induce cell death in leukemia

... bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporation and TopoTarget A/S), were examined in ...ly with both agents to induce cell death in human CLL cells. Romidepsin and belinostat are histone deacetylase (HDAC) inhibitors. "To the best of our knowle...
Belinostat in Biological Technology

Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL

Update on the Regulatory Strategy for Belinostat in PTCL COPENHAGEN, Denmark, September 5 /PRNewswire-FirstCall/ -- TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial for belinostat in PTCL (...

CuraGen Sells Ownership of Belinostat to TopoTarget A/S

- CuraGen to receive approximately $45 million in cash, stock and future milestone payments - - Provides updated financial guidance for 2008 - - Conference call to be hosted today at 9:00 a.m. EDT - BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- ...

CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma

BRANFORD, Conn., Dec. 19 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center ...

TopoTarget Successfully Buys Back Full Control of Belinostat

Consolidates the Global Rights for the Product TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product TopoTarget Acquires US & RoW Rights From CuraGen Corporation COPENHAGEN, April 22 /PRNewswire/ -- -...

CuraGen Reports Third Quarter 2008 Financial Results

...50 per share, for the same period in 2007. Net income for the nine months ended September 30, 2008 and 2007 was primarily due to a gain of the sale of belinostat and a gain on the extinguishment of debt in the second quarter of 2008, and the sale of 454 Life Sciences Corporation in the second quarter of 2007. ...

CuraGen Reports Fourth Quarter and Year End 2007 Financial Results

...n excellent position to advance our core products, belinostat and CR011-vcMMAE, toward registrational developmen...d quarter of 2008; -- Updated Phase II results of belinostat in combination with carboplatin and paclitaxel...8; and -- Initiate Phase III trial of intravenous belinostat for the treatment of peripheral T-cell lymphom...

CuraGen Appoints Clinical Oncologist as VP of Medical Development

...or the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promis...

CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer

...w on three oncology programs including velafermin, belinostat and CR011-vcMMAE. "Tim has done an outstanding jo... Phase II results from an ongoing trial evaluating belinostat in combination with carboplatin and paclitaxel... October from an ongoing trial evaluating oral belinostat for the treatment of advanced solid tumors at ...
Other Tags
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... older Americans suffer from depression, often brought on by ... a project that followed the lives of thousands ... that Internet use among the elderly can reduce the ... "That,s a very strong effect," said Shelia Cotten, a ... media who led the project. "And it all has ...
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
(Date:4/17/2014)... Press journal Current Biology on April 17 ... lives. The Brazilian insects, which represent four distinct but ... the first example of an animal with sex-reversed genitalia. ... several different animals, Neotrogla is the only ... says Kazunori Yoshizawa from Hokkaido University in Japan. , ...
(Date:4/17/2014)... the genetic information of DNA is used to ... numerous different functions in living organisms. Messenger RNA ... expression, by relating the genetic information of DNA ... , By examining the different types and ... at a given time, researchers can determine which ...
(Date:4/17/2014)... full of wild animals and plant life, but there,s ... churning away in the soil, decomposing organic matter and ... role these fungi play in ecological systems, their identities ... scientists has generated a genetic map of more than ... was published this week in the Proceedings of ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Rapid and accurate mRNA detection in plant tissues 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
Other Contents